Intalight™ Receives CE Mark for Revolutionary DREAM OCT™ Imaging
In a significant achievement for the field of ophthalmology,
Intalight™, a leader in advanced ocular technologies and Optical Coherence Tomography (OCT), has proudly announced the receipt of CE marking for their latest imaging platform,
DREAM OCT™. This certification signifies that DREAM OCT is now authorized for commercial distribution across the European Union, allowing ophthalmologists to implement cutting-edge imaging technology in clinical settings.
The acronym
DREAM encapsulates key features of this platform:
Deep imaging depth,
Rapid sweeping speed,
Extensive scan range,
Accurate results, and
Multimodal imaging capabilities. With these attributes, DREAM OCT™ provides some of the highest quality imaging available in the optical coherence tomography market today.
Shawn Peng, the CEO and founder of Intalight™, expressed his pride in this accomplishment, stating, "We are extremely proud to receive the CE mark for DREAM OCT in Europe. This achievement enables us to supply ophthalmologists in Europe with state-of-the-art technology that translates to better diagnostic outcomes for patients."
The DREAM OCT™ platform stands out for its ultra-wide imaging range, boasting 130-degree OCTA scans. This revolutionary technology utilizes 12mm tunable lasers to achieve unparalleled image quality of the retina, retinal vasculature, and a significant portion of the vitreous body. The front segment imaging capabilities also extend to a remarkable depth of 16.2mm (in air), enabling comprehensive imaging from the cornea to the anterior portion of the vitreous body in a single scan. With longer wavelengths, DREAM OCT™ can penetrate opaque areas of the lens and vitreous body effectively, ensuring high-resolution images that facilitate accurate diagnosis and treatment.
Bing Li, the company’s co-founder and CEO, explained, "Over the past few years, ophthalmology specialists have expressed the need for solutions that deliver rapid, accurate diagnostic results with significant imaging depth. DREAM OCT provides a full set of retinal imaging features catering to the most demanding clinical and research applications, exceeding any solutions previously known to medical professionals."
The development of DREAM OCT™ was driven by feedback from retina specialists, general ophthalmologists, and their patients. Its exceptional imaging accuracy aims to enhance care quality and result in improved patient outcomes. The experiences gained from devices utilizing DREAM OCT technology have already contributed to over 160 peer-reviewed publications.
Joe Garibaldi, Intalight's Chief Commercial Officer, added, "This is fantastic news for Intalight as we conclude the waiting period for bringing our product to the European market. We are eagerly looking forward to the opportunity to launch this innovative solution in the United States as well. We anticipate further development of our prestigious network of global institutions and ophthalmologists following the recent CE approval and the expected FDA clearance."
As a pioneer in clinically approved devices for ultra-wide angle imaging, Intalight is currently collaborating with leading retinal research institutions and private eye care clinics in the United States, Europe, and Asia.
Founded by a group of scientists and veterans from Silicon Valley, Intalight Inc. aims to develop the most advanced ophthalmic technologies. With headquarters in Silicon Valley, along with branches in Shanghai and Luoyang, the company leverages tuned laser technology to create an imaging device that integrates depth, speed, extensive scan range, accurate detection, and multimodal imaging capabilities, known collectively as
DREAM OCT™. This powerful imaging tool has become essential for many ophthalmologists, supporting not only routine clinical practice but also expanding scientific knowledge through research.
For more information about Intalight and DREAM OCT™, please visit
Intalight's website, connect on LinkedIn, or follow on Facebook.